These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21078606)

  • 1. Review: Antiplatelet drugs: what comes next?
    Kei AA; Florentin M; Mikhailidis DP; Elisaf MS; Liberopoulos EN
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):9-26. PubMed ID: 21078606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiplatelet agents: ticlopidine and clopidogrel. Antiplatelet therapy but at what cost?
    Black C; Paterson KR
    Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):277-303. PubMed ID: 11770173
    [No Abstract]   [Full Text] [Related]  

  • 3. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance.
    Jennings LK
    Crit Pathw Cardiol; 2009 Mar; 8(1):20-8. PubMed ID: 19258834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Mohler ER
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S1-6. PubMed ID: 19213065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of the interindividual variability in response to antiplatelet drugs.
    Rocca B; Patrono C
    J Thromb Haemost; 2005 Aug; 3(8):1597-602. PubMed ID: 16102024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet agents: current drugs and future trends.
    Messmore HL; Jeske WP; Wehrmacher W; Coyne E; Mobarhan S; Cho L; Leya FS; Moran JF
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):87-117, vi. PubMed ID: 15639110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin and clopidogrel resistance: should we worry about?
    Cuisset T; Cayla G
    Minerva Med; 2010 Feb; 101(1):35-47. PubMed ID: 20228719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ; Guzman LA; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antiplatelet drugs: beyond aspirin and clopidogrel.
    Siddique A; Butt M; Shantsila E; Lip GY
    Int J Clin Pract; 2009 May; 63(5):776-89. PubMed ID: 19392926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.
    Kuliczkowski W; Witkowski A; Polonski L; Watala C; Filipiak K; Budaj A; Golanski J; Sitkiewicz D; Pregowski J; Gorski J; Zembala M; Opolski G; Huber K; Arnesen H; Kristensen SD; De Caterina R
    Eur Heart J; 2009 Feb; 30(4):426-35. PubMed ID: 19174428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent.
    Satish B; Tressa K; Harish CR
    Crit Pathw Cardiol; 2007 Mar; 6(1):24-5. PubMed ID: 17667883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facts and controversies of aspirin and clopidogrel therapy.
    Faxon DP; Freedman JE
    Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period.
    Hall R; Mazer CD
    Anesth Analg; 2011 Feb; 112(2):292-318. PubMed ID: 21212258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond.
    Shalito I; Kopyleva O; Serebruany V
    Am J Ther; 2009; 16(5):451-8. PubMed ID: 19262362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary atherothrombotic disease: progress in antiplatelet therapy.
    Badimon L; Vilahur G
    Rev Esp Cardiol; 2008 May; 61(5):501-13. PubMed ID: 18462654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
    Lordkipanidzé M; Diodati JG; Pharand C
    Pharmacol Ther; 2009 Aug; 123(2):178-86. PubMed ID: 19426760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.